Company News

Bioocus is at the forefront of developing next-generation CAR-T therapies. The recent publication by Dr. Chunrong Tong and her team at Lu Daopei Hospital highlights critical advancements and challenges in the application of second-generation CD19 CAR-T therapies in pediatric patients, showcasing Bioocus's commitment to innovative cancer treatment.

A groundbreaking study highlights the remarkable effectiveness of CAR-T cell therapy in treating B-cell Acute Lymphoblastic Leukemia (B-ALL). The research, involving collaboration with BIOOCUS and Lu Daopei Hospital, demonstrates significant advancements, establishing the therapy as a critical treatment option.

Researchers from Lu Daopei Hospital and international collaborators explore cutting-edge CAR-T cell therapies, offering hope for patients with B cell malignancies. This study highlights advancements in design and application, showcasing promising results and the potential for future innovations.

Recent clinical studies reveal that 4-1BB-based CD19 CAR-T cells demonstrate superior antitumor efficacy compared to CD28-based CAR-T cells in treating relapsed or refractory B cell acute lymphoblastic leukemia (r/r B-ALL).

A recent study at Lu Daopei Hospital demonstrated the high efficacy and safety of low-dose CD19 CAR-T cell therapy in treating refractory or relapsed B acute lymphoblastic leukemia (B-ALL) patients. The research, which included 51 patients, showcased a remarkable complete remission rate with minimal side effects.

Lu Daopei Hospital and Hebei Senlang Biotechnology have announced promising findings from their recent study on the safety and efficacy of CAR-T therapy for acute B cell leukemia. This collaboration highlights the potential of novel CAR-T cell designs to enhance patient outcomes.

A new study led by Dr. Zhi-tao Ying from Peking University Cancer Hospital has demonstrated the safety and efficacy of IM19 CAR-T cell therapy in treating relapsed and refractory B-cell hematologic malignancies. Published in the Chinese Journal of New Drugs, the study reports that 11 out of 12 patients achieved complete remission with no severe adverse effects, showcasing the potential of IM19 as a promising treatment option for patients with limited alternatives.

The 2024 Annual Training for Clinical Blood Management and Transfusion Technology in Sanhe City was successfully held at Yanda Ludaopei Hospital. This event aims to enhance clinical blood management and transfusion safety through comprehensive training sessions attended by over 100 healthcare professionals from various medical institutions.

Ensuring a safe and comfortable treatment experience for leukemia patients involves meticulous daily care, including environmental sanitation, personal hygiene, nutrition, and appropriate exercise. This guide provides essential tips for effective daily care to support recovery.

A recent study highlights the efficacy and safety of NS7CAR-T cell therapy in treating relapsed or refractory T-cell acute lymphoblastic leukemia (R/R T-ALL) and T-cell lymphoblastic lymphoma (R/R T-LBL). This therapy offers new hope for patients with these aggressive forms of cancer.

The 12th Annual Lu Daopei Hematology Forum is set to take place on August 23-24, 2024, at the Beijing International Convention Center. Join us for insightful discussions and the latest advancements in hematology.

A phase I clinical study of CD7 CAR-T for R/R AML by Daopei Lu's team debuts at ASHThe 65th Annual Meeting of the American Society of Hematology (ASH) was held offline (San Diego, USA) and online on December 9-12, 2023.Our scholars made a great show of this co...